[HTML][HTML] Breakthrough in targeted therapy for non-small cell lung cancer

Z Ye, Y Huang, J Ke, X Zhu, S Leng, H Luo - Biomedicine & …, 2021 - Elsevier
Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of
lung cancer which causes more and more mortality in recent years. NSCLC accounts for …

[HTML][HTML] Recent advances in non-small cell lung cancer targeted therapy; an update review

M Araghi, R Mannani, A Heidarnejad maleki… - Cancer Cell …, 2023 - Springer
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …

[HTML][HTML] Targeted therapies for advanced non-small cell lung cancer

X Ai, X Guo, J Wang, AL Stancu, PMN Joslin, D Zhang… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Lung cancer is a serious health problem and the leading cause of cancer death worldwide,
due to its high incidence and mortality. 85% of lung cancers are represented by the non …

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications

A Custodio, M Méndez, M Provencio - Cancer treatment reviews, 2012 - Elsevier
Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents

C Gridelli, A Rossi, P Maione - Oncogene, 2003 - nature.com
Conventional treatment of non-small-cell lung cancer (NSCLC) has apparently reached a
plateau of effectiveness in improving the survival of NSCLC patients. Although neoadjuvant …

[HTML][HTML] Review of the current targeted therapies for non-small-cell lung cancer

KSH Nguyen, JW Neal, H Wakelee - World journal of clinical …, 2014 - ncbi.nlm.nih.gov
The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

[HTML][HTML] Recent progress in targeted therapy for non-small cell lung cancer

Y Xiao, P Liu, J Wei, X Zhang, J Guo… - Frontiers in Pharmacology, 2023 - frontiersin.org
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …

[HTML][HTML] New molecularly targeted therapies for lung cancer

S Sun, JH Schiller, M Spinola… - The Journal of clinical …, 2007 - Am Soc Clin Investig
Lung cancer is the leading cause of cancer death worldwide. The disease is particularly
difficult to detect, and patients often present at an advanced stage. Current treatments have …

[HTML][HTML] Emerging targeted therapies in advanced non-small-cell lung cancer

S Li, GS de Camargo Correia, J Wang, R Manochakian… - Cancers, 2023 - mdpi.com
Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

[HTML][HTML] Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

U Majeed, R Manochakian, Y Zhao, Y Lou - Journal of hematology & …, 2021 - Springer
Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …